Acute cardiac care & resuscitation
Characteristics, management, and outcomes of active cancer patients with cardiogenic shock
Main finding · 1-year mortalityResult — go to the resultHazard ratio 3.61 CI 1.29–10.11Authors' conclusion
Active cancer patients accounted for almost 7% of all cases of cardiogenic shock. Early mortality was the same regardless of active cancer or not, whereas long-term mortality was significantly increased in patients with active cancer.
Study context
- Population
- Patients admitted for cardiogenic shock of all aetiologies, French critical care units, April–October 2016 (FRENSHOCK)
- Participants
- 772 patients
- Exposure
- Active cancer vs no active cancer
- Active cancern = 51
- Outcome
- 1-year mortality
- Follow-up
- 1 year
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Hazard ratio
3.61
CI 1.29–10.11
P = 0.015
Active cancervs No active cancer
HR 3.61 (CI 1.29–10.11); P = 0.015
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Norepinephrine use | P = 0.005 |
| Norepinephrine-dobutamine combination | P = 0.005 |
| Mechanical circulatory support | P = 0.016 |
30-day mortality
- Active cancer not associated with 30-day mortality in multivariable analysis
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Characteristics, management, and outcomes of active cancer patients with cardiogenic shock. Eur Heart J Acute Cardiovasc Care. Published 6 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →